
-
UroGen Pharma NasdaqGM:URGN UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Location: 400 Alexander Park Drive, Princeton, NJ, 08540, United States | Website: https://www.urogen.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
113.5M
Cash
195.9M
Avg Qtr Burn
-26.76M
Short % of Float
15.21%
Insider Ownership
8.46%
Institutional Own.
98.32%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
JELMYTO® (mitomycin) Details Carcinoma , Cancer | Approved Quarterly sales | |
UGN-102 (mitomycin) Details Bladder cancer | PDUFA Approval decision | |
UGN-103 Details Bladder cancer, Cancer | Phase 3 Update | |
UGN-104 Details Cancer, Urothelial cancer | Phase 3 Initiation | |
UGN-301 Details Non-muscle invasive bladder cancer | Phase 1 Data readout |